“[O]ur results add to a growing body of evidence suggesting the importance of considering potential neuropsychiatric sequelae of COVID-19 infection,” wrote researchers from Massachusetts General Hospital, Harvard Medical School, Harvard University, and Northeastern University, Boston, Massachusetts; Rutgers University, New Brunswick, New Jersey; and Northwestern University, Evanston, Illinois.
The web-based survey study, which included Patient Health Questionnaire-9 responses, found that 2046 participants, or 52.4% of those surveyed, met criteria for symptoms of major depressive disorder an average of 4.2 months after they experienced acute symptoms of COVID-19.
Half of COVID-19 Survivors Report Moderate to Severe Depression
Moderate or greater symptoms of major depression were more likely among younger respondents, men, and those who reported greater COVID-19 symptom severity, regression models found. Additionally, headache during acute COVID-19 infection was associated with a greater likelihood of depressive symptoms at the time of the survey.
Nevertheless, the authors continued, the findings point to the need for strategies to mitigate elevated depressive symptoms experienced by many so patients after COVID-19 illness.
Source: